Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.46 |
| ▸ | LPL | P06858 | 8/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 2/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14857542 | 0.85 | TDP2 (0.43) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL17423566 | 0.84 | CA1 (0.53) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL20995580 | 0.84 | SMN1; SMN2 (0.53) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL19619142 | 0.84 | ALDH1A1 (0.53) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL5899727 | 0.82 | LPL (0.65) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL29719698 | 0.82 | LIPG (0.51) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL13860162 | 0.82 | LIPG (0.51) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL5243207 | 0.82 | CA1 (0.61) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL121746 | 0.81 | EGFR (0.42) | LIPGLPLEGFRAR | |
| SCHEMBL22400889 | 0.81 | MEN1 (0.44) | LIPGLPLEGFRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109970741-A | Amino pyridazine ketone compound as kinases inhibitor | 江苏恒瑞医药股份有限公司 | 2019-07-05 | — | — | CN | disclosed |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
| CN-106573001-B | Aminopyridazinone compounds as protein kinase inhibitors | 江苏恒瑞医药股份有限公司 | 2019-01-29 | — | — | CN | disclosed |
| EP-3166608-B1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2018-12-12 | — | — | EP | disclosed |
| US-20180251465-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-09-06 | — | — | US | disclosed |
| US-9951077-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-9951077-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| EP-3166608-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016007185-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Eternity Bioscience Inc. (US) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251465-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | LIPG 3777/4885LPL 3870/4885CA1 3988/4885 |
| US-20170152264-A1 | AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS | SSB, MAPKAPK5, BCL9 | LIPG 3777/4885LPL 3870/4885CA1 3988/4885 |
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | SSB, MAPKAPK5, BCL9 | LIPG 3777/4885LPL 3870/4885CA1 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.